his majesty king abdullah ii ibn al-hussein · president of the european association of nuclear...

His Majesty King Abdullah II Ibn Al-Hussein

His Royal Highness Crown Prince Al-Hussein Bin Abdullah II

The 1st International Conference ofThe Arab Society of Nuclear Medicine ( ARSNM ) & The Jordanian Society of Nuclear Medicine ( JOSNM )

Wednesday. 29.Aug. 2018

P


5

Welcome MessageOn behalf of the organizing committee, it gives me a great pleasure to welcome you to the 1st International conference of the Arab Society of Nuclear Medicine (ARSNM) & Jordanian Society of Nuclear Medicine (JOSNM) to be held during 29th-31st August 2018, in Landmark Hotel, Amman, Jordan.

The Conference will be held in collaboration with the King Hussein Cancer Center (KHCC), the International Atomic Energy Agency (IAEA), the World Federation of Nuclear Medicine and biology (WFNMB), the Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB), Canadian Association of Nuclear Medicine (CANM) and under the auspices of the European Association of Nuclear Medicine (EANM).

This conference will bring you an array of renowned top-notch speakers from leading organizations and institutions worldwide as well as from the Arab world. We are enthusiastic that our speakers will address central issues and challenges experienced in areas of nuclear medicine advancement and provide participants with information on variety of development opportunities in our field. The conference will provide the participating nuclear medicine physicians and professionals with a venue to maintain advanced knowledge and skills in various aspects of nuclear medicine with focus on theranostics, hybrid modalities, PET/CT and nuclear oncology.

This 3-day conference has been granted 17 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®) and 17 CME credits from the Jordan Medical Council.

Being the first conference of ARSNM, this event will be a great opportunity to enforce communication and cooperation, exchanging the knowledge, ideas and experiences in our field and eventually to highlight the significant role of nuclear medicine specialty in the healthcare in the Arab World.

A scientific exhibition is also a part of the conference where leading companies will display their latest products that have found clinical acceptance with particular relevance to enhance patient care.

The social program will reflect the Jordanian hospitality and will allow for great networking opportunities among attendees

We cordially express our gratitude to our partner organizations, invited speakers, sponsors, attendees and the organizing company for their supports.

Dr. Akram Al-IbraheemPresident of the ConferencePresident of ARSNM & JOSNM


6

PRESIDENT OF THE CONFERENCEDr. Akram Al-Ibraheem

JOSNM ORGANIZING COMMITTEEDr. Akram Al-Ibraheem, PresidentDr. Abedallatif Alsharif, Vice-presidentDr. Khaled Alkhawaldeh, Chair of Scientific CommitteeDr. Mais Al Halaseh, Chair of Social CommitteeDr. Abdullah Al Zreiqat, Treasurer

ARSNM ORGANIZING COMMITTEEDr. Akram Al-Ibraheem, President (Jordan)Dr. Mohamad Haider, Vice-president (Lebanon)Dr. Batool AlBalooshi (UAE)Dr. Naima Albalushi (Oman)Dr. Fairouz Mohamad (Yemen)Dr. Amjad Albader (Iraq)Dr. Huda Al-Nuaime (Qatar)

CME DIRECTORDr. Thomas Pascual, IAEA


7

SpeakersInternational Faculty


8

Markus Schwaiger (Germany)Chief Medical Officer & CEO of Klinikum rechts der Isar der Technischen University München, GermanyAcademic Career and Research AreasProf. Schwaiger (b. 1950) has been Director of Nuclear Medicine at TUM’s rechts der Isar clinic since 1993. His main area of research is the use of multimodal imaging to visualize and quantify biological processes. His research involves the use of positron emission tomography (PET) in cardiology and oncology. He is Director of the German Research Foundation’s Collaborative Research Center 824, which deals with the use of molecular imaging for selecting and monitoring oncological therapies. The diagnosis and treat-ment of thyroid endocrine and neuroendocrine diseases is an area of special interest in the nuclear medicine department.

Prof. Schwaiger studied medicine at Freie Universität Berlin and Freiburg University. His career as a doctor and researcher has taken him to the UCLA School of Medicine (Los Angeles, USA) and the University of Michigan (Ann Arbor, USA), among other places, where he was professor of internal medicine until 1993. Prof. Schwaiger is a member of the Bavarian Academy of Sciences and the Leopoldina. He has an honorary doctorate from the University of Varna, Bulgaria.

Courses / AwardsMaximiliansorden (2010)Hermann Blumgart-Preis, Society of Nuclear Medicine (2006)Von Hevesy Medal of Hungarian Society of Nuclear Medicine (2005)Henry Wagner Lecture, Society of Nuclear Medicine, Los Angeles (2002)Distinguished Scientist Award, Academy of Molecular Imaging, AMI, San Diego (2002)

Andrew Scott (Australia)President of World Federation of Nuclear Medicine & Biology (WFNMB)

Prof. Andrew Scott is Director, Department of Molecular Imaging and Therapy, Austin Health; Laboratory Head at the Olivia Newton-John Cancer Research Institute; and Pro-fessor of Medicine, University of Melbourne, and La Trobe University. He has an Inter-national reputation as a clinician/scientist with expertise in molecular imaging, cancer therapy, and in both preclinical and clinical drug development. He is the current Pres-ident of the World Federation of Nuclear Medicine and Biology, and is on the Board of many significant organisations including the Australian Nuclear Science and Technol-ogy Organisation (ANSTO), Chair of the board of Cancer Trials Australia, and Chair of the International Relations Committee of the Australian and New Zealand Society of Nuclear Medicine. He is also a Fellow of the Royal Australasian College of Physicians, Fel-low of the Australian Academy of Health and Medical Sciences, Fellow of the Australian Institute of Company Directors, and in 2017 was awarded Member (AM) in the General Division of the Order of Australia.

Prof. Scott has published 320 peer reviewed papers and 21 book chapters, principally in the areas of oncology and molecular imaging. He is actively involved in the training and mentoring of young scientists and clinicians and currently supervises several doctoral students in addition to post-doctoral fellows and Nuclear Medicine trainees.


9

Jun Hatazaw (Japan)President of Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB)

Jun Hatazawa is Professor of Nuclear Medicine and tracer kinetics at Osaka University

Graduate School of Medicine. He is also the director of Medical Imaging Center for

Translational Research.

Prof Hatazawa is the President of Asia Oceania Federation of Nuclear Medicine and

Biology from 2017 to 2020. He is engaged in the “Atoms for Medicine” project where

nuclear energy is used for diagnostic imaging and radionuclide therapy for patients.

This project covers radionuclide production with accelerator, purification of target ra-

dionuclide, labelling biomolecules for target cells, dosimetry and safety, nuclear med-

icine education/practice, and disposal of medical radioactive waste. He is promoting

this project in Asia Oceania nuclear medicine community and beyond.

Kristoff Muylle (Belgium)President of the European Association of Nuclear Medicine (EANM)

After completion of his medical studies in 1999 and his training in Nuclear Medicine

in 2004 at the Free University of Brussels (VUB), Kristoff Muylle started his professional

career at the Jules Bordet Cancer Institute in Brussels, where his work mainly focused

on clinical and research activities related to nuclear medicine procedures in (hemato-)

oncology with a specific interest in radioimmunotherapy and immuno-PET. In 2015, he

joined the clinical staff of the nuclear medicine department at the University Hospital of

Brussels (UZ Brussel) and will combine this activity with a position as nuclear medicine

physician at AZ Delta in Roeselare starting from July 2018.

Kristoff Muylle was President of the Belgian Society of Nuclear Medicine from 4/2014

until 4/2016. He joined the Board of the European Association of Nuclear Medicine

(EANM) as President-Elect in 2015 and serves currently as EANM President for 2017-

2018.


10

Diana Paez (Austria)Head of Nuclear Medicine Section, IAEA

Head of the Nuclear Medicine and Diagnostic Imaging Section (NMDI) within the Divi-sion of Human Health, Department of Nuclear Sciences and Applications at the Interna-tional Atomic Energy Agency (IAEA). Born in Bogota, Colombia, has a nuclear medicine degree from the National Cancer Institute - Javeriana University. Completed fellowship training in nuclear cardiology at the St. Luke’s–Roosevelt Hospital and nuclear oncology (PET) at the Memorial Sloan Kettering Cancer Center in New York, USA in 1997. Acquired a Master’s Degree in Communication and Education from the Autonoma University in Barcelona, Spain in 2013. Served as Assistant Professor of Radiology at El Bosque Uni-versity. In 2009, she joined the IAEA and in November of 2013 became Head of NMDI.

She places special emphasis on strengthening the competences of nuclear medicine and diagnostic imaging professionals in Member States through different mechanisms, particularly by using information and communication technologies for education-al purposes, organization of international conferences, and multiple training courses around the world. She also focuses on increasing the number of female professionals participating in IAEA activities and encouraging female professionals from LMICs to join graduate programmes on nuclear sciences.

She has co-authored over 100 scientific articles and books, and presented over 300 lec-tures at international conferences.

Medhat Osman (USA)Professor of RadiologyDirector of Nuclear Medicine & PET/CT Nuclear MedicineTraining Program Director, Saint Louis University

Dr. Osman is a Tenured Professor and the Medical Director of the Division of Nuclear

Medicine and PET/CT at Saint Louis University, Saint Louis, MO, USA. He is board certi-

fied in Nuclear Medicine. Dr. Osman obtained both PhD and Master of Science degrees

from The Johns Hopkins University in Baltimore, MD. His Nuclear Medicine residency,

Oncology fellowship and PET/CT fellowship were also at The Johns Hopkins University

in Baltimore, MD, USA.

Dr. Osman’s research interests include PET CT, oncology, neurology, and cardiology. He

has co-authored over 85 peer-reviewed journal articles, four textbook chapters, and

more than 250 abstracts. Recently, he completed a 6 months sabbatical at Peter Mac-

Callum cancer centre in Melbourne, Australia, where he was actively involved in Thera-

nostics training and research.


11

Homer Macapinlac (USA)Department Chair, Department of Nuclear Medicine, Division of Diag-nostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

James E. Anderson Distinguished Professor of Nuclear Medicine, Department of Nu-

clear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson

Cancer Center, Houston, TX

Department Chair, Department of Nuclear Medicine, Division of Diagnostic Imaging,

The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The

University of Texas MD Anderson Cancer Center, Houston, TX

Dong Soo Lee ( S. Korea)President-Elect, World Federation of Nuclear Medicine & Biology (AOF-NMB) Professor and ChairmanMolecular Medicine and Biopharmaceutical Sciences at Seoul National University and Seoul National University Hospital, Seoul Korea

Professor and Chairman, Department of Molecular Medicine and Biopharmaceutical

Sciences, Seoul National University . Director, BioMAX/N-Bio Seoul National University

- Past-President of Korean Society for Nanomedicine - Past-President of Korean Society

of Nuclear Medicine - Past-President of Korean Society of Human Brain Mapping. Prof

Dong Soo LEE Published >300 articles in SCI journal (1999-now) including Nature, Na-

ture Protocol. - Received KOFST, Pfizer, SNUMC Alumni Academic Awards in 2001, 2003,

2006. - Editor-in-Chief, Nucl Med Mol Imaging (2014- ) - Editorial Board of Journal of Nu-

clear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, Journal

of Nuclear Cardiology, , European Journal of Nanomedicine.


12

Wim J.G. Oyen (UK)President-elect, European Association of Nuclear Medicine (EANM)

Professor Wim Oyen was appointed full Professor of Nuclear Medicine and Molecular Imaging at The Institute of Cancer Research and Head of the Department of Nuclear Medicine of The Royal Marsden NHS Foundation Trust, London, UK in September 2015. Before coming to the UK, he was a Board Certified nuclear medicine physician and full Professor of Nuclear Medicine at the Radboud University Medical Centre Nijmegen, The Netherlands, serving as Head of the Department of Nuclear Medicine, Member of the Board of the Medical Staff and Director of the Research Institute for Oncology of Rad-boudUMC.

Professor Oyen’s main research interests are molecular imaging in oncology and infec-tious diseases and radionuclide therapy of cancer. He is the (co-)author of more than 600 original science and review articles in international peer-reviewed journals. He is currently actively involved in the European Association of Nuclear Medicine (Board Member, President-elect, past-Congress Chair), the European Cancer Organisation (Past-Treasurer), and the International Cancer Imaging Society (President). Professor Oyen is a member of the Editorial Board of The Journal of Nuclear Medicine and the European Journal of Nuclear Medicine and Molecular Imaging.

Habib Zaidi (Switzerland)Head of PET Instrumentation & Neuroimaging Laboratory (PINLab)Dept. of Medical Imaging and Information Sciences Geneva University Hospital, Geneva, Switzerland

Chief physicist and head of the PET Instrumentation & Neuroimaging Laboratory at Geneva University Hospital and faculty member at the medical school of Geneva Uni-versity and several other medical schools. He is actively involved in developing imaging solutions for cutting-edge interdisciplinary biomedical research and clinical diagnosis, hybrid imaging instrumentation (PET/CT and PET/MRI), modelling medical imaging systems using the Monte Carlo method, development of computational anatomi-cal models and radiation dosimetry, image correction, reconstruction, quantification and kinetic modelling techniques in emission tomography as well as statistical image analysis in molecular brain and oncologic imaging, and more recently on novel design of dedicated PET and PET/MRI scanners. He is editor, associate editor and reviewer of several reputed journal in radiology and nuclear medicine , he is also the founding Editor-in-Chief (scientific) of the British Journal of Radiology (BJR)|Open and Senior Ed-itor for the British Journal of Radiology . His academic accomplishments in the area of quantitative PET imaging have been well recognized by his peers and by the medical imaging community at large since he is received many awards and distinctions among which the most recent was the 2017 IBA-Europhysics Prize given by the European Phys-ical Society (EPS). Prof. Zaidi has been an invited speaker of over 130 keynote lectures and talks at an International level, has authored over 490 publications, including 236 peer-reviewed journal articles in prominent journals and 32 book chapters.1


13

Hossein Jadvar (USA)Associate Professor of Radiology, Keck School of Medicine, USCAssociate Professor of Biomedical Engineering Viterbi School of Engi-neering (USC)

Dr. Jadvar is a tenured associate professor of radiology (Keck School of Medicine) and biomedical engineering (Viterbi School of Engineering) at the University of Southern California (USC) with hospital appointments at the USC Keck Medical Center, USC Norris Comprehensive Cancer Center, and the LAC+USC Medical Center. He also served as a visiting associate in bioengineering at the California Institute of Technology in Pasade-na, Calif. Dedicated to lifelong learning, Dr. Jadvar received his BS in chemical engineer-ing from Iowa State University in Ames, Iowa, in 1982, followed by a MS in biomedical engineering from the University of Wisconsin in Madison, Wis., in 1984, and a MS in computer engineering, as well as a PhD in bioengineering, from the University of Michi-gan in Ann Arbor, Mich., in 1986 and 1988, respectively. He then attended the University of Chicago Pritzker School of Medicine in Chicago, Ill., for his MD degree (1993). He received his MPH degree from Harvard University in Cambridge, Mass., in 2005 and an Executive MBA from the University of Southern California in Los Angeles, Calif., in 2007. He was a clinical fellow in positron emission tomography with the Harvard Medical School Joint Program in Nuclear Medicine, in Boston, Mass., during 1998-99; a diagnos-tic radiology and nuclear medicine resident at Stanford University, in Stanford, Calif., during 1994-98; and an intern in internal medicine at the University of California San Francisco, Calif., during 1993-94. He has also completed a number of executive educa-tional certificate programs at Harvard Medical School in Boston, Mass., the University of Cambridge in the UK, the University of Oxford in the UK, and the Wharton School of Business at the University of Pennsylvania in Philadelphia, Penn. Dr. Jadvar is on the ed-itorial boards of the Journal of Nuclear Medicine, the European Journal of Nuclear Med-icine and Molecular Imaging, Molecular Imaging and Biology, Radiology (Consultant to the Editor), American Journal of Roengenology (Assistant Editor), and Clinical Nuclear Medicine (Deputy Editor), and many others. He is the past president of the American College of Nuclear Medicine (ACNM) and the past recipient of the SNMMI Mark Tetal-man Young Investigator Award, the Western Regional SNMMI Distinguished Scientist Award, the Academy of Radiology Research Distinguished Investigator Award, and the inaugural Prof. Ajit Padhy Oration Memorial Award from the World Association of Radi-opharmaceuticals and Molecular Therapy (WARMTH), and the USC Excellence in Men-toring Award. He is a National Institutes of Health (NIH) funded investigator and serves on multiple NIH review panels (with one term as a chartered member), Department of Defense, and the Imaging Technology and Informatics Peer Review Panel of the Can-cer Prevention and Research Institute of Texas (CPRIT). He is a fellow of ACNM, SNMMI, and the USC Center for Excellence in Research. He is an established nuclear medicine expert for the International Atomic Energy Agency (IAEA). He has written more than 120 journal articles, has published 4 books, 28 book chapters, 9 patents and has given more than 250 invited speaker presentations and visiting professorships at numerous national and international venues. His research interests include applications of PET in clinical outcome research and in translational molecular imaging research with particu-lar current interest in prostate cancer. (http://www-hsc.usc.edu/~jadvar)


14

Christopher Obrien (Canada)Medical Director of the Division of Nuclear Medicine at Brantford Gener-al HospitalStratford General Hospital and Pembroke Regional Hospital, Canada (CANM)

Dr. O’Brien is the Medical Director of the Division of Nuclear Medicine at Brantford General Hospital, Stratford General Hospital and Pembroke Regional Hospital. Dr. O’ Brien has a BSc in neurophysiology, MD from McGill university and F.R.C.P. in Nuclear Medicine at the University of Western Ontario and Diagnostic Radiology from the same university.

Among many leading position of nuclear medicine in Canada, Dr. O’Brien held the position of Adjunct Professor at Department of Nuclear Medicine at London Health Sciences Centre and was the President of Canadian Association of Nuclear Medicine [2001 to 2004]

Currently he is also a Member Ad Hoc Medical Isotope Expert Panel Health Canada [2007 to present] and he is on the Board of Directors of Canadian Association of Nucle-ar Medicine since 2001. Dr. O’Brien has several scientific publications in full texts and abstracts.

Samir Ezzidin (Germany)Director & Professor of Nuclear Medicine at Saarland University, Germany

After graduation from Medical School in Frankfurt a.M. / Germany in 1997, Samer Ezziddin went on to a one- year residency in Medicine and Endocrinology at the University of Cologne. He passed the USMLE including the Clinical Skills Assessment in Philadelphia/MA, and achieved full ECFMG certification in 1999.

During his residency and subsequent time as Assistant Medical Director in Nuclear Med-icine at the University of Bonn he introduced 177Lu- based peptide receptor radio-nuclide therapy (PRRT) in 2004 and developed the targeted therapy program. As the Deputy Director in Bonn (2008- 2014) he restructured and expanded the Radioemboliza-tion routine, achieved the first European dual- license for Resin and Glass Microsphere Radioembolization, and introduced intra- arterial PRRT.His German PhD (Habilitation) in Nuclear Medicine focused on outcome predictors in PRRT. He is a well recognized international expert on neuroendocrine tumors and target-ed radionuclide therapy and has extensively published in the area of dosimetry and mo-lecular imaging for planning and monitoring radioembolization (SIRT). The master thesis of his accompanying studies in Medical Device Clinical Sciences (MSc) at the University of Bonn addressed the different impact of radioembolization devices. Other fields of exper-tise and activities involve thyroid & prostate cancer and multimodality imaging (PET- CT, SPECT- CT).Samer Ezziddin is a Member of the (10 man) Radionuclide Therapy Committee of the Eu-ropean Association of Nuclear Medicine (EANM), the Therapy Committee of the German Society of Nuclear Medicine (DGN), the National Expert Group for Radioembolization (SIR-Tranet) and the Steering Committee for the CIRSE Registry for SIR- Microsphere Therapy (CIRT). Since August 2014 Professor Ezziddin is Head of the Nuclear Medicine Department at Saarland University Hospital. With his therapeutic focus in oncology and devotion to targeted treatment he aims at individualizing and optimizing radionuclide- based target-ed tumor therapy.


15

Thomas Pascual (Austria)Technical Officer & Nuclear Medicine PhysicianSection of Nuclear Medicine. IAEA

Dr Thomas NB Pascual is Nuclear Medicine Physician with special interest and expertise in Paediatric Nuclear Medicine and PET/CT, Quality Management Systems in Nuclear Med-icine, Health Professions Education and project management and capacity building. He trained in Nuclear Medicine at UST and obtained his fellowship training at the Children’s Hospital at Westmead in Greater Sydney, N.S.W. Australia and his Master’s Degree in Health Professions Educations (M.H.P.Ed) at the University of Santo Tomas in the Philippines. He is currently finishing his Doctorate in Education at University of Glasgow, in Scotland, UK. He has delivered speciality lectures on (1) Adult and Paediatric Nuclear Medicine and its appl ication in Oncology/ PET/CT (2) Health Professions Education in the Nuclear Medicine and (3) Quality Management Audits in Nuclear Medicine Practice internationally and (4) Project design and Results based monitoring and evaluation system. Since 2007, he has been the Executive Director of the Asian School of Nuclear Medicine (ASNM), the edu-cational arm of the Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM) responsible in identifying and liaising with national and international organizations and experts in Nuclear Medicine for capacity building initiatives in developing countries. He is a professional staff member of the International Atomic Energy Agency (IAEA) as a Nu-clear Medicine Physician under the Section of Nuclear Medicine and Diagnostic Imaging, Division of Human Health working in several capacity building projects promoting the peaceful use of Nuclear Techniques in Human Health. He has received the Merit Award from the IAEA twice (2014, 2017) for exceptionally meritorious performance in his tasks. Last February 2016, he received Distinguished Filipino Nuclear Medicine Award for Inter-national Leadership on the occasion of the 50th anniversary Philippine Society of Nuclear Medicine. Research highlights at https://www.researchgate.net/profile/Thomas_Pascual/contributions

Henry Bom (S.Korea)Chairman , The Asian Regional Cooperative council for Nuclear MedicineProfessor of Nuclear Medicine at the Chonnam National UniversityMedical School (CNUMS) and Hospital, Gwangju, Korea

Professor of nuclear medicine at the Chonnam National University Medical School

(CNUMS) and Hospital, Gwangju, Korea. He graduated from CNUMS at 1982 and was

trained internal medicine and nuclear medicine in Korea. He worked as the deputy direc-

tor and general director of CNU Hwasun Hospital from 2006 to 2010, as the president of

the Korean Society of Nuclear Medicine from 2008 to 2010, as the chairman of the Asian

Regional Cooperative Council for Nuclear Medicine (ARCCNM) from 2010 to 2013. His re-

search interests are RI therapy for thyroid cancer and cardiac hybrid imaging.


16

Salem Yuoness (Canada)Director – Nuclear Medicine Department Diagnostic imaging servicesBrandon Regional Health Centre. Brandon, MB Canada

Education: Medical school: University of Tripoli (Libya).Nuclear Medicien Residency Training Program: University of Western Ontario (Canada)Nuclear Cardiology and Cardiac CT fellowship: Western University (Canada)PET CT fellowship : Western University (Canada)Chief Resident: Nuclear Medicine Residency training program at University of Western Ontario.Fellowship representative: Nuclear Cardiology fellowship.

Qualification: 1. Certification Board of Nuclear Medicine from Royal College of Physicians and Sur-geons in Canada2. American Board of Nuclear Medicne.3. European Board certification in Nuclear Medicine.4. Certification Board of Nuclear Cardiology from American Society of Nuclear Cardiology.5. CCD Certified Clinical Densitometrist from ISCD (International society for clinical den-sitometry).6. Medical council of Canada Qualifications exams (MCCEE, MCCQ1, and MCCQ2).

Director: Division of Nuclear Medicine Diagnostic Imaging Department Brandon Regional Health Centre Memeber at large (Board Member):Canadian Association of Nuclear Medicine Board Member: Manitoba Bone density program committee.

Stephan Maus (Germany)Radiochemist, at Saarland University, Germany

- 2006-2018 Laboratory of Radiochemistry, Clinic and Polyclinic for Nuclear Medicine, Uni-versity Medical Centre Mainz.

- 2018- Department of Nuclear Medicine , Saarland University Medical Center and Saar-land University, Faculty of Medicine

- Article (27)- Chapter (2)- Conference Paper (6)- Presentations (6)- Poster (17)

- Best Scientific Poster “Synthesis of novel Phenothiazine derivatives Potential new com-pounds for the 18F-labelling of imaging agents “; DGN Leipzig 2009

- Area of research includes “Synthesis and preparation of new 18F- labeled compounds, Synthesis and preparation of new 68Ga- labeled compounds, Synthesis and preparation of new drug delivery systems based on biodegradable polymers, Synthesis and prepara-tion of a possible surrogate for 90Y labeled SIRT, spheres based on bio-degradable poly-mers & In-Vivo and in-vitro studies with the previously mentioned compounds”.


17

Bela Kari (Hungary)Research Associate, Engineer-Physicist at Semmelweis UniversityDept. of Diagnostic Radiology and Nuclear Medical Center

He has MSc. in Electronic Engineering from the Technical University of Budapest,

and a Ph.D. in Vibration Analysis By Laser Beam, Technical University of Budapest,

Department of Atomic Physics in 1984. He held several prestigious research and

project leading positions, most recently he is research Associate, Engineer-Physi-

cist at Semmelweis University Dept. of Diagnostic Radiology and Nuclear Medical

Center and invited Lecturer, Teaching MSc. Medical Physics Students at Budapest

University of Technology and Economics Institute of Nuclear Technics January

2010 – Present

He is also a scientific adviser of the nuclear medical and multi-modality image

processing technology at Mediso Ltd. January 1999 – Present.

Jakub SimecekPHD in Radiochemistry and Developing New Molecules

Dr Jakub , Holds a PHD in chemistry . Dr Jakub has been active in the field of de-

velopment of Novel Radio metalled targeting compounds and their transfer from

bench to bed side . he has been working on Chemical design of labelling process-

es , optimisation of biochemical properties of active substances in the preclinical

properties of active substances in the preclinical evaluation as well as selection

of the candidates for the first human studies . his expertise is focused on Ga68 la-

belled diagnostics compounds , Lu177 based therapeutic molecules and recently

also alpha targeted therapies .


18

Abdelhamid H. Elgazzar (Kuwait)Chairman, Department of Nuclear MedicineFaculty of Medicine – Kuwait University

Prof. Elgazzar is currently the Chairman, Department of Nuclear Medicine, Faculty of Medicine/ Kuwait University.

Prof . Elgazzar obtained the American Board of Pathology (Anatomic and Clinical) in 1983 and then dedicated his medical career to nuclear medicine with keen attention on pathophysiology of health and disease, he obtained the American Board of Nuclear Medicine in 1985

During his extensive career Prof. Elgazzar has received several prestigious international honors and rewards in appreciation of his great contribution to nuclear medicine, he held several leading positions in nuclear medicine among them he was the chief of nuclear medicine division at Tufts University New England Medical Center, Boston, USA in 2002-2003.

Prof. Elgazzar has an extensive list of 119 peer reviewed original articles, he is editor and author of 14 books and 5 book chapters, in addition to 165 published abstracts.

Regional Faculty


19

Akram Al-Ibraheem (Jordan)President of Arab Society of Nuclear MedicinePresident of Jordanian Society of Nuclear MedicineChairman, Department of Nuclear Medicine King Hussein Cancer Center, Jordan

Dr. Al-Ibraheem got his medical degree from Aleppo University in Syria and he obtained

his training in nuclear medicine from the Jordanian Royal Medical Services in Amman

and Kilinikum rechts der Isar in Munich, Germany. He got his boards in nuclear medi-

cine from the European Union of Medical Specialties (FEBNM), Jordan medical Coun-

cil (JBNM) and Asian nuclear Medicine Board (FANMB). He is also certified in nuclear

cardiology from the American Certification Board of Nuclear Cardiology (DCBNC). Dr.

Al-Ibraheem completed a specialized fellowship in PET/CT and nuclear oncology at

Technische Universität München (TUM) in Germany in 2008 and 2009.

Dr. Al-Ibraheem has authored and published many articles in international peer-re-

viewed journals focusing on molecular imaging and the role of PET/CT in cancer man-

agement and he is an editorial board member of several international journals. He is

the principal investigator for several ongoing clinical trial and multi-centric research

projects.

Since 2012, he has served as an expert for the international Atomic Energy Agency

(IAEA) and he is a national counterpart for the Jordanian Atomic Energy agency (JAEA)

for the nuclear medicine projects. He has been the course director for many regional

and international workshops in Amman as joint projects between King Hussein Cancer

Center and the IAEA.

Dr. Al-Ibraheem introduced state-of-the art nuclear medicine services to KHCC and Jor-

dan such as DOTATOC and PSMA PET/CT imaging as well as peptide receptors radionu-

clide therapy (PRRT) and PSMA-ligand radionuclide therapy (PLRT).

Dr. Al-Ibraheem is currently the president of Arab Society of Nuclear Medicine, ARSNM

(2014-2018) and the President of Jordanian Society of Nuclear Medicine, JOSNM (2016-

2019) and the Vice-President of the Asia Oceania Federation of Nuclear medicine and

Biology

He is a faculty and board examiner of the Asian nuclear medicine board and the Jor-

danian board of nuclear medicine. He is the director of nuclear oncology fellowship at

King Hussein Cancer Center which receives many fellows from the region.


20

Mohamad Haidar (Lebanon)Associate Professor of Clinical RadiologyVice-president, Arab Society of Nuclear MedicineDirector of Nuclear Medicine Division, PET/CT and Cyclotron facilities Diagnostic Radiology DepartmentAmerican University of Beirut Medical Center)

Dr Haidar Mohamad, is an Associate professor of Nuclear Medicine at the American University of Beirut, he is the director of Nuclear Medicine division and Cyclotron facil-ity. He obtained his training in Nuclear Medicine from the University Paris VII in France in 2000, and completed his academic training in several fellowship or training positions at the Bichat Claude Bernard Hospital, Saint Antoine Hospital in Paris and at the Zurich hospital. He was also President of the Lebanese Nuclear Medicine Society since Novem-ber 2011 till May 2015.

Dr Haidar has reviewed, authored and published many articles in international and na-tional peer-reviewed journals focusing on the role of Nuclear Medicine and PET/CT in oncology and cancer management. Dr Haidar has delivered many talks and papers in national, regional and international meetings. He has received an award for his research work in 2009 at the Middle East Oncology Congress, (COMO VIII), Beirut, Lebanon. Dr. Haidar is currently a member in different national and international scientific and med-ical societies.

Batool Essa Albalooshi (UAE)Consultant & Head of Dubai Nuclear Medicine & Molecular Imaging Centre, MD, Facharzt

Consultant & Head of Dubai Nuclear Medicine & Molecular imaging center.

Dr. AlBalooshi had her residency in Nuclear medicine at Dubai health Authority, she ob-tained the European board of Nuclear Medicine (EBNM) in 2011 and then obtained the Facharzt in nuclear medicine and molecular imaging after training at Technische Universi-ty Munich (TUM), klinikum rechts der Isar from 2006 to 2012.

Dr. AlBalooshi is the representative of Dubai health Authority in International Atomic En-ergy Agency (IAEA) projects in Dubai, she also represents UAE in Asian school of nuclear medicine. She also is strongly involved in promoting nuclear medicine at national and international levels, Dr. Albalooshi is currently the vice president of Asia Oceania society of nuclear medicine and is the president of Emirates society of Nuclear Medicine and molecular imaging 2015-up to date. She authored and coauthored several peer reviewed scientific papers.


21

Abdulaziz Saleh Al Sughair (Saudi Arabia)Chairman of Department of Radiology at King FaisalSpecialist Hospital & Research Center in the Kingdom of Saudi Arabia, Asso-ciate Professor of Nuclear Medicine with Affiliation with Al-Faisal University

Dr. Al-Sugair is the Chairman of Department of Radiology at King Faisal Specialist Hos-pital & Research Centre in the Kingdom of Saudi Arabia, he is also Associate Professor of Nuclear Medicine with Affiliation with Al-Faisal University. Dr. Al-Sugair has obtained his MBBS from the Faculty of Medicine, Jordan University in 1998. His first medical residen-cy was at King Faisal Specialist Hospital and Research Centre/ Department of Medical Imaging Services, then at the University of British of Columbia/Department of Diagnos-tic Radiology in Vancouver/ Canada (1992-1994), at Western Ontario/Canada (1994-1996) followed by one year fellowship at the same institute. He also had a fellowship as Clinical and Research Associate Department of Radiology at Duke University Medical Center/USA in the period from 1997 to 1999.

Dr. Al-Sugair is strongly involved in education and teaching of nuclear medicine in Saudi Arabia and in the region, he has organized and participated in several national, regional and international workshops and courses. Dr. Al-Sugair had published more than 35 articles in peer reviewed journals, more than 30 abstracts and 3 book chapters.

Malik Juweid (Jordan)Professor, Department of Radiology & Nuclear Medicine, Jordan University

Dr. Malik Juweid is a professor of radiology and nuclear medicine and head of nuclear

medicine at the University of Jordan. He is American-board certified in nuclear medicine

since 1992 and has extensive experience in both general nuclear medicine and PET/CT

imaging. His major research interests are PET/CT imaging of lymphoma and radioimmu-

notherapy of of lymphoma, medullary thyroid and ovarian cancers. He has published over

100 articles in peer-reviewed journals, including in the New England Journal of Medicine

and the Journal of Clinical Oncology and has edited a book on PET imaging in oncology.

He has also obtained more than 5 million dollars of research funding from the US National

Institutes of Health and the Food and Drug Administration.


22

Naima Khamis Al-Bulushi (Oman)Director of Nuclear Medicine Department at Royal Hospital in Oman

Dr. Naima is the director of nuclear medicine department at Royal Hospital in Oman.

She has a Fellowship of Radiology at Royal College of Surgeons in Ireland (FFR RSCI)

and she has completed Nuclear Medicine Fellowship training program at King Faisal

Hospital.

Dr. Naima is involved in the planning of all new nuclear medicine centers in Oman, in

staffing of the new molecular imaging center equipped with PET/CT and the first Cy-

clotron Centre in Oman. She is deeply involved in teaching and training medical staff

and radiologists in nuclear medicine and is committed to quality management and in

nuclear medicine.

Dr. Naima has several peer reviewed scientific publications, posters and abstracts.

Khaled Alkhawaldeh (Jordan)Consultant and head of Nuclear Medicine- Royal Medical Services and Part time Consultant of Nuclear Medicine- King Hussein Cancer Center

- Consultant and head of Nuclear Medicine- Royal Medical Services- 2015- until now)

- Part time Consultant of Nuclear Medicine- King Hussein Cancer Center (2017 until now).

•M.B.B.S degree in Medicine – Jordan University- 19971

•Jordanian Board in Nuclear Medicine-2004.

•Fellowship in PET/ and PET/CT- Hospital of University of Pennsylvania- 2005.

•American Certification Board in Nuclear Cardiology-2006

•Fellowship in the European Board in Nuclear Medicine- 2011.


23

Abdullah Alqarni (Saudi Arabia)Head of Nuclear Medicine Section PrinceSultan Military Medical City, Saudi Arabia

Dr. Abdullah was born in Sabt Alalaya, Assir region in Saudi Arabia and graduated from

King Saud University. He obtained his medical degree at Abha Medical College. He has

double Qualifications of Radiology from Jordanian Medical Council of Radiology and in

Nuclear Medicine from (Paris Groupe Hospitaliere) and Paris11 University. His residen-

cy was in Paris Hospitals Group and his fellow training of Multihybrid modalities (PET/

CT and PET/MRI) was in the Geneva University Hospital where he worked as a Chief De

Clinic for about 2 years.

Dr. Abdullah currently is a consultant and director of Nuclear Medicine and Hybrid mo-

dalities department, of a military Rank as Colonel in Prince Sultan Medical Military City.

He has interest in hybrid imaging of Oncology and has many publications in interna-

tional journals and has participated in many international activities with membership

in many regional and international societies and organizations.

Abedallatif AlSharif (Jordan)Tenured Professor at the Department of Radiology and Nuclear Medi-cine, Faculty of Medicine, University of Jordan

Dr. Abedallatif AlSharif is a Tenured Professor at the department of Radiology and Nu-

clear Medicine/ faculty of medicine/University of Jordan. He founded nuclear medicine

services at the university of Jordan and National center for diabetes and endocrinology.

Currently he is the medical director of Afia radiotherapy and nuclear medicine center.

He is graduate of the University of Jordan, holds the Italian board in nuclear medicine

and molecular imaging and had advanced training in Pet/Ct at Stanford University.

Dr. AlSharif’ s research interests include PET/CT, oncology, endocrinology, and cardiol-

ogy. He has co-authored 30 peer-reviewed journal articles, five textbook chapters, and

more than 30 abstracts.


24

Kusai Almoqbel (Jordan)Professor & Chair, Department of Radiology & Nuclear MedicineJordan University of Science and Technology

Combined Nuclear medicine/Internal Medicine residency, University of Tennessee/Univ.

of Louisville from 1998-2001

PET fellowship, university of Tennessee, 2001-2002

American Board of nuclear medicine since 2002

Full-time faculty, department of radiology and nuclear medicine

School of Medicine, Jordan University of Science and Technology since 2003 till now

Chief of nuclear medicine section since 2003 till now

Chairman of radiology department since 2016 till now

Research publications: Breast cancer and bone metastasis, hepatobiliary scan and thyroid scan

Recent Publications:

Bone Marrow Metastasis Is an Early Stage of Bone Metastasis in Breast Cancer Detected

Clinically by F18-FDG-PET/CT Imaging.

Al-Muqbel KM.

Biomed Res Int. 2017;2017:9852632. doi: 10.1155/2017/9852632. Epub 2017 Aug 13.

Effectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment

of Bone Metastases in Breast Cancer.

Al-Muqbel KM, Yaghan RJ.

Medicine (Baltimore). 2016 May;95(21):e3753. doi: 10.1097/MD.0000000000003753.

Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on

PET/CT in breast cancer patients.

Al-Muqbel KM, Yaghan RJ, Al-Omari MH, Rousan LA, Dagher NM, Al Bashir S.

Nucl Med Commun. 2016 Jun;37(6):593-601. doi: 10.1097/MNM.0000000000000481.

Osteoblastoma is a metabolically active benign bone tumor on 18F-FDG PET imaging.

Al-Muqbel KM, Al-Omari MH, Audat ZA, Alqudah MA.

J Nucl Med Technol. 2013 Dec;41(4):308-10. doi: 10.2967/jnmt.113.127332. Epub 2013 Oct 21.

Value of baseline and follow-up whole-body bone scans in detecting bone metastasis in

high-risk breast cancer patients.

Al-Muqbel KM, Yaghan RJ.

Nucl Med Commun. 2013 Jun;34(6):577-81. doi: 10.1097/MNM.0b013e328360d6d5.


25

Nabil Iqeilan (Qater)Medical Physicist Chairman of Education and raining MEFOMP Hamad Medical Corporation

Mr. Iqeilan has MSc in Medical Physics, from the Radiation Physics Department, Univer-

sity of Stockholm (Karolinska Institute), Sweden. (2006); he is Certified as a Qualified

Medical Physicist Professional (A Swedish license to practice).

Mr. Iqeilan has joined Hamad Medical Corporation, in Doha, Qatar, in 2012. He has more

than 18 years experience in the department of Biomedical Physics, King Faisal Special-

ist Hospital, Riyadh, Saudi Arabia.

Mr. Iqeilan has extensive experience in radiation protection, radiation dosimetry, phys-

ics of medical imaging, commissioning, acceptance and routine QC testing of x-ray

equipment. Mr. Iqeilan in involved in internal teaching of staff in theoretical and prac-

tical radiation protection of staff and patients.

Hind Aschawa (Morocco)President of Moroccan Society of Nuclear Medicine

Dr. ASCHAWA was born in Meknes, Morocco in 1975. Held his Doctorate in 2004 from

the Faculty of Medicine, Hassan the second University, Casablanca, Morocco.

• In 2009, she started as an Assistant Professor in Nuclear Medicine Dept Ibnou Rochd

University Hospital Center, Casablanca Morocco, then promoted to Professor in 2017.

• Dr. ASCHAWA has been president of nuclear medicine association since 2015.

• Dr. Aschawa now lives in Morocco with his husband and his two daugthers.

Education Background:

• 2017-present: Professor of High Studies at the Nuclear Medicine Department, Ibn

Rochd University Hospital Center and University Hassan II of Casablanca.

• 2013-2017: Professor Agregate at the Nuclear Medicine Department, Ibn Rochd

University Hospital and the Faculty of Medicine Center of Casablanca.

• 2009-2013: Professor Assistant at the Nuclear Medicine Department, Ibn Rochd

University Hospital, Casablanca.

• 2008-2009: Nuclear Medicine Resident trainee at the Nuclear Medicine Department,

Ibn Rochd University Hospital, Casablanca.

• 2004: Medical Doctorale.


26

Fahad Marafi (Kuwait)Director General of Jaber Al-AhmadCenter for Molecular ImagingPresident of Kuwait Society of Nuclear Medicine and Molecular Imaging

M.Yahiaoui (Algeria)Algerian Association of Liberal Nuclear Medicine Practitioners


27

scientific program


28

Day 1: 29th August 2018 (Hall Rum) Registration - Opening Session

Time

08:00 Registration

09:00 -10:00 Opening Session Opening and Welcome Addresses

10:00 -10:30 COFFEE BREAK

Session 1: Nuclear Medicine; Where are we going?

Chairpersons:Prof. Kristoff Muylle (Belgiun, EANM)Dr. Abdulghani Shakhashero (IAEA)

Time Title Speaker Learning Objectives

10:30 -10:55Global Trends in

Nuclear Medicine

Prof. Andrew Scott

President of World Federation of Nuclear

Medicine & Biology. (WFNMB)

- Describe the global status of

nuclear medicine.

-Identify the opportunities for

nuclear medicine.

- Trace the challenges facing nuclear

medicine.

10:55 -11:20

Molecular Imaging as Tool

for Precision Medicine

Prof. Markus Schwaiger

Medical Officer & CEO of Klinikum Rechts Der Isar

Der Technischen Universität München,

Germany.

- Recognize the advances in nuclear

medicine through innovations

- Propose the success in molecular

imaging and theranostics.


29

11:20 -11:45

Global Perspectives on

Nuclear Medicine with Focus on

Middle East

Prof. Diana PaezHead of Nuclear

Medicine Section. (IAEA)

- Describe the different situations

of nuclear medicine globally.

- Review the status of nuclear.

medicine in the middle east.

- Integrate the iaea initiatives to

support nuclear medicine.

11:45 -12:25

Hussein Abdel Dayem Lecture Understanding

principles of Creativity: Impact

on Professional Development

Prof. AH. ElgazzarChairman,

Department of

Nuclear Medicine,

Faculty of Medicine/

Kuwait University

- Know the proper definitions of creativity,

innovation and motivation.

- Understand the conducting factors and

obstacles to creativity.

- Understand the impact of using

creativity principles in research, teaching,

clinical practice and management.

- Understand the outcome of

understanding and using principles of

creativity on professional and society

development.

12:25 -12:30 Discussion

12:30 -13:30 LUNCH


30

Session 2: Theranostics Updates

Chairpersons:Dr. Sami Al-Khatib (Jordan, JOS) Prof. Christopher Obrien (Canada, CANM)

Time Title Speaker Learning Objectives

13:30 -13:50Theranostics: the Future of Nuclear

Medicine

Prof.Medhat Osman

Professor of Radiology Director of Nuclear Medicine & PET/CT Nuclear Medicine Training Program

Director Saint Louis University.

- Discuss theoretical and practical information on the biology, indications, diagnosis and current therapeutic options for the treatment of NETs. - Demonstrate a framework for the integration of PRRT into current practice of conventional cancer treatment modalities. - Integrate PRRT in the clinical practice through the use of standardized treatment protocols.

13:50 -14:20

Status Quo and Recent Advances

in PRRT of Advanced Nen

(Neuroendocrine Neoplasms)

Prof.Samir Ezzidin

Director & Professor of Nuclear

Medicine At Saarland University,

Germany.

- Illustrate the status of PRRT - when to apply in current algorithms. - Describe relationship of grading and treatment success in PRRT . - Recognize if low-G3 (G3A) nen potential candidates for PRRT ? - Indications for PRRT in different subsets of gep NET and BP nen. - Debates for earlier application of PRRT in treatment algorithms. - Plan augmentation methods for PRRT .

14:20 -14:40

The Role of Camelids in Molecular

Imaging and Theranostics.

Prof.Kristoff Muylle

President of the European Association of Nuclear Medicine.

(EANM)

- The interest of receptor imaging / immuno-PET. - Structure and characteristics of nanobodies. - Potential diagnostic and therapeutic applications of radiolabeled nanobodies.

14:40 -15:00

F-18 FBPA PET and Boron

Neutron Capture Therapy for Intractable

Cancer

Prof.Jun HatazawaPresident of Asia

Oceania Federation of Nuclear Medicine and

Biology (AOFNMB).

- Illustrate the principle of boron

neutron capture therapy.

- Descripe the role of boron

neutron capture therapy in

intractable cancer.



31

Session 3: PET/CT 1Chairpersons:Prof. Hikmat Abed-Alrazeq (Jordan, KHCC)Prof. Andrew Scott (Australia, WFNMB)

Time Title Speaker learning objectives

15:15 -15:35 FDG PET/CT in

Oncology

Dr. Salem Yuoness Director - Nuclear

Medicine Department Diagnostic Imaging

Services Brandon Regional

Health Centre. Brandon, Mb Canada.

- Provide an overview of the impact of PET/CT imaging on the management of cancer patients. - Review the current use of PET/CT in the multi-disciplinary. care of oncology patients, with emphasis on its utility in adaptive therapeutic strategies.

15:35 -16:00 PET/CT in Breast

Cancer

A/Prof. Hossein Jadvar

Associate Professor of Radiology

Keck School of Medicine of USC

Associate Professor of Biomedical Engineering

Viterbi School of Engineering of USC

University of Southern California.

- To review briefly the histopathological types and demographics of breast cancer. - To discuss the diagnostic and prognostic utility of FDG PET/CT (and pet/mri) in breast cancer. - To describe briefly the design and utility of positron emission mammography (pem) imaging systems.

16:00 -16:25

Therapy Response Assessment in Solid Tumors:

Timing and Interpretation.

(Focus on Lymphoma,

Including Immunotherapy/

Adoptive Cell Therapy)

Prof.Homer Macapinlac

Department Chair, Department of

Nuclear Medicine, Division of Diagnostic

Imaging, the University of Texas

MD Anderson Cancer Center, Houston, TX.

- Review the criteria for response

assessment in solid tumor.

- Illustrate the proper timing

for response assessment to

conventional and immunotherapy.

- Interpret the findings encountered

in pet scan in response assessment .

16:25 -16:50

Impact of FDG PET/CT on the Management

of Patients with Colorectal Cancer

Prof. Wim J.g. OyenEANM President-

Elect .

- Indications for - in colorectal cancer. - Position of FDG-PET/CT as compared to other imaging modalities. - Impact of FDG-PET/CT on patient management.



32

Session 4: Hybrid Imaging & PET/MRI

Chairpersons:Prof. Medhat Osman (USA)A/Prof. Khaled Alkhawaldeh (Jordan, JOSNM)


17:00 -17:30

Hybrid Imaging: Looking Back (PET/CT) and

Moving Forward (PET/MRI)

Prof. Habib ZaidiHead of PET

Instrumentation & Neuroimaging

Laboratory (Pinlab)Geneva University

Hospital Dept. of Medical

Imaging and Information Sciences Geneva, Switzerland.

- Describe the principles, basic

technology, and clinical operation

of hybrid imaging.

- Understand the challenges

of developing hybrid imaging

instrumentation.

- Discuss the pros/cons of current

PET/CT and PET/MRI clinical

systems.

- Understand the limitations

of hybrid imaging technology

and present potential future

developments in the field.

17:30 -18:00PET/MRI:

Potential Clinical Application







- To review briefly the design of

currently available hybrid PET/MRI

systems.

- To discuss potential clinical

applications of PET/MRI in

neurology, cardiology, oncology,

and pediatrics.

- To compare PET/MRI and PET/CT

in various conditions.

- To describe the acr-snmmi

joint statement on pet/mri

interpretation credentialing.


33

Day 2: 30th August 2018 (Hall Rum)

Session 5: Education & Quality & PET/CT 2

Chairpersons:A/Prof. Mohamad Haidar (Lebanon, ARASNM)Dr. Mais Alhalaseh (Jordan JOSNM)


08:30 - 09:00

Educational Process and

Practice Issues for Nuclear Medicine

Physicians and Technologists

in Canada: Provincial,

National, and International

Challenges

Prof. Christopher Obrien

Medical Director of the Division of

Nuclear Medicine at Brantford General Hospital, Stratford

General Hospital and Pembroke Regional Hospital, Canada.

(CANM)

- Understand the royal college

training program in canada and

routes to practice.

- Understand national and

provincial impact on nuclear

medicine practice and patient

access.

- Distinguish international

Endeavors of the canadian

association of nuclear medicine:

a: GMP harmonization.

b: The pangea project.

09:00 - 09:20

Examining Quality

Management Audits in Nuclear Medicine Practice

as a Lifelong Learning Process.

Dr. Thomas PascualTechnical Officer & Nuclear Medicine Physician, Section

of Nuclear Medicine. (IAEA)

- Explore the critical issues and

challenges surrounding lifelong.

- Learning for professionals within

the organizational context of

nuclear medicine practice.

- Critically examine how quality

management audits in nuclear

medicine practice (quanum) can be

considered a lifelong.

- Learning opportunity to

instill a culture of quality

to improve patient care.

- Describe narratives and

observations of quanum as a

lifelong learning process from an

auditor’s perspectives.


34

9:20 - 9:40

Nuclear Cardiology Practice in

Asia: Analysis of Radiation

Exposure and Best Practice

for Myocardial Perfusion Imaging.

Dr. Thomas PascualTechnical Officer & Nuclear Medicine Physician, Section

of Nuclear Medicine. (IAEA)

- Analysis of radiation exposure and best practice for myocardial perfusion imaging. - Examines the current status of radiation exposure to patients in myocardial perfusion imaging (MPI) in asia. - Describe possible explanations for the persistence of inappropriate MPI imaging.- Summarize recommendations of the 8 best practices in MPI.

9:40 - 10:05

FDG PET/CT in Response

Assessment of Lymphoma; an

Update.

Prof. Malik Juweid

Professor, Department of

Radiology & Nuclear Medicine, Jordan

University.

- Describe the role of FDG PET

in response assessment in

different types of lymphoma.

- Recognize the strength

and limitations of FDG

PET in lymphoma.

- Integrate the FDG PET in the

management plan of lymphoma.

10:05 - 10:30

FDG PET/CT in Breast Cancer

Bone Metastasis; Jordanian

Experience and Research Results.

Prof. Kusai Almoqbel

Professor & Chair, Department of

Radiology & Nuclear Medicine, Jordan

University of Science and Technology.

- Describe the role of FDG PET in

assessment of breast cancer bone

metastases.

- Illustrate the research results of

FDG PET in assessment of breast

cancer bone metastases.

10:30 - 11:00 COFFEE BREAK


35

Session 6: SPECT/CT

Chairpersons:Prof. Jun Hatazawa (Japan, AOFNMB)Dr. Batool Albalooshi (UAE, ARSNM)Dr. Fareed Resheq (Jordan)


11:00 -11:30

Ventilation/Perfusion Lung Scanning using

SPECT

Prof. Christopher Obrien

Medical Director of the Division of Nuclear Medicine at Brantford

General Hospital, Stratford General

Hospital and Pembroke Regional Hospital, Canada (CANM).

- Understand the strength and

weakness of V/P spect and CT

pulmonary angiography (CTPA) in

the diagnosis of pulmonary.

- Embolism (PE) in the following

situations:

1 : Acute PE.

2 : PE during pregnancy.

11:30 -12:00

Hybrid Imaging, Diagnostic Value

and Impaction on Patient's

Management: SPECT CT in

Differentiated Thyroid Cancer

Dr. Salem YounessDirector - Nuclear

Medicine Department Diagnostic Imaging

Services Brandon Regional

Health Centre. Brandon, Mb Canada.

(CANM)

- Added value of hybrid imaging compared to planar imaging. - Ability to differentiate physiological pattern from pathological uptake. - Reducing pitfalls and increase diagnostic accuracy. - Impaction on patient's management.

12:00 -12:30

Multimodality Imaging of

Vertebral and Chronic Active )

steomyelitis

Prof. AH. Elgazzar Chairman,

Department of Nuclear Medicine,

Faculty of Medicine/ Kuwait University

- Understand the pathophysiology of chronic and vertebral osteomyelitis related to imaging.- Understand the problems in diagnosis of chronic active osteomyelitis and vertebral osteomyelitis.- Understand the utilization of different functional and morphologic imaging modalities for diagnosis of chronic and vertebral osteomyelitis.- Identify the current recommendations for the diagnosis of chronic active osteomyelitis and vertebral osteomyelitis.


36

12:30 -12:45

Various Image Processing Procedures to Improve Myocardial

SPECT Studies

Dr. Bela Kari Research Associate, Engineer-Physicist

at Semmelweis University Dept. of

Diagnostic Radiology and Nuclear Medical

Center.

- Discuss advances in image

processing of myocardial SPECT

studies.

- Understand the new processing

procedures to improve myocardial

SPECT studies.

12:45 -13:00

Multi-Modality 3D Imaging

Technology in Brain SPECT Application

Dr. Bela Kari Research Associate, Engineer-Physicist

at Semmelweis University Dept. of

Diagnostic Radiology and Nuclear Medical

Center.

- Discuss advances in in brain

SPECT applications.

- Understand the new technology

in 3D brain SPECT.

13:00 -14:00 LUNCH


37

Session 7: Theranostics & Regional Research

Chairpersons:Prof. Abedallatif Alsharif (Jordan, JOSNM) Dr. Kamal Abo-Alrob (Jordan)Dr. Thomas Pascual (Austria, IAEA)


14:00 -14:25 Radionanomedicine

for in Vivo Nanotheranostics

Prof.Dong Soo Lee

President-Elect, WFNMB Professor and

Chairman, Molecular Medicine and

Biopharmaceutical Sciences

Seoul National University and Seoul National University

HospitalSeoul Korea.

- Understand what is

radionanomedicine, and what it is

for, especially, in vivo theranostics.

- Envision what kind of unmet

clinical needs will be solved by

radionanomedicine.

- Take one best example of

successful radionanomedicine.

14:25 -14:50

Quantitative Molecular

Imaging: Past, Present, and Any

Future?

Prof. Habib ZaidiHead of PET

Instrumentation

& Neuroimaging

Laboratory Geneva

University Hospital,

Department of

Medical Imaging and

Information Sciences

Geneva, Switzerland.

- Describe the physical factors

degrading image quality and

affecting quantitative accuracy in

PET imaging.

- Discuss potential algorithmic

solutions enabling to reduce image

artifacts and improve quantitative

accuracy of PET data.

- Understand the pros/cons of

various image-derived PET metrics.

- Understand the limitations of the

proposed solutions and list potential

future developments in the field.


38

14:50 -15:15

King Faisal Specialist

Hospital and Research Center

Experience in Radionuclide

Therapy

A/Prof. Abdulaziz Al-SughairChairman of

Department of Radiology at King

FaisalSpecialist Hospital &

Research Center in the Kingdom Of

Saudi Arabia, Associate Professor of Nuclear Medicine

WithAffiliation with Al-Faisal University.

- Describe the advances in regional radionuclide therapies.- Identify the regional potentials of regional researches in KFSH and the region.

15:15 -15:30The Most Rare Radionuclide

Dr. Jakub Simecek

PhD in Radiochemistry and Developing New Molecules, Munich,

Germany



39

Session 8: Nuclear Cardiology

Chairpersons:Prof. Diana Paez (Austria, IAEA)A/Prof. Abdulaziz Al-Sughair (Saudi Arabia, KFSH)


16:00 -16:30New Applications of Cardiac PET/CT

Prof. Henry Bom Professor of Nuclear

Medicine at the

Chonnam National

University Medical

School (Cnums) and

Hospital, Gwangju,

Korea.

- Describe the current status of

PET/CT nuclear cardiology.

- Understand the new PET/CT

approaches in nuclear cardiology.

16:30 -17:00

Multimodal Imaging with

PET/MRI in Cardiology

Prof. Marcus Schwaiger

Medical Officer &

CEO of Klinikum

Rechts Der Isar

Der Technischen

Universität München,

Germany.

- Describe the current status of

PET/MRI nuclear Cardiology.

- Understand the new approaches

in nuclear PET/MRI.

- Identify the Strength and

challenges in the future of pet/mri

cardiology


40

Day 3: 31st August 2018 (Hall Rum)

Session 9: Theranostics in Immunotherapy and Response Assessment

Chairpersons:Prof. Henry Bom (S. Korea, ARCCNM)Dr. Abdullah Zreiqat (Jordan, JOSNM)


8:30 - 08:50

Theranostics in Oncology; the

Nuclear Medicine Perspectives

A/ Prof. AkramAl-Ibraheem

President of Jordanian Society & Arab Society

of Nuclear Medicine Chairman,

Department of Nuclear Medicine,

King Hussein Cancer Center, Jordan

- Discuss the rationales for

theranostics in oncology.

- Illustrate the principles of

theranostics in nuclear medicine

- Integrate theranostics into clinical

practice.

08:50 - 9:20

Appropriate use Criteria for 18F-FDG PET/

CT in Restaging and Treatment

Response Assessment of Malignant

Disease







- To review the history of Imaging

Based response criteria in

treatment of cancer.

- To summarize the currently

available response criteria.

- To delineate the shortcomings

of traditional anatomy-based

criteria and the evolution of new

metabolic-based criteria.

09:20 - 09:40

Theranostics for Immune Based

Therapy of Cancer

Prof. Andrew Scott

President of World Federation of Nuclear

Medicine & Biology. (WFNMB)

- Understand the contribution of theranostics in the era of immune therapy. - Identify the specific theranostics methodologies in immunotherapy of cancer.


41

09:40 -10:00

Positron Emission Mammography (PEM): New Era

of Molecular Imaging

Dr. Fahad MarafiDirector General

of Jaber Al-Ahmad Molecular Imaging

CenterPresident of Kuwait Society of Nuclear

Medicine and Molecular Imaging.

- Understand types and differences

among breast-dedicated imaging

systems in nuclear medicine.

- Learn the diagnostic and

quantitative abilities of PEM.



42

Session 10: Radionuclide Therapy and Thyroid Cancer

Chairpersons:A/Prof. Odeh Altaleb (Jordan )Dr. Fahad Marafi (Kuwait, KSNMMI)


10:30 -10:55

The Asian Approach to

Manage Thyroid Cancer

Prof. Henry Bom Professor of Nuclear

Medicine at the Chonnam National University Medical

School (Cnums) and Hospital, Gwangju,

Korea.

- Learn how heterogeneous is the management of thyroid cancer in asia.- Learn clinical factors influencing the management of thyroid cancer in asia.- Learn recommended practices for the management of thyroid cancer in asia.

10:55 -11:20Challenges in Management of Thyroid Cancer

Dr. Batool Albaloohi

Consultant & Head of Dubai Nuclear

Medicine & Molecular Imaging

Centre, Md, Facharzt.

- Discuss some challenges in management of thyroid cancer.- Learn how to manage challenging cases of thyroid cancer.

11:20 -11:40

Literature Review of PET/CT Radio-Pharmaceuticals

in the Diagnosis of

Neuroendocrine Tumors

Dr. Abdullah Alqarni

Head of Nuclear Medicine Section

Prince Sultan Military Medical City, Saudi

Arabia.

- Distinguish the different PET radiotracers used d for NET.- Discuss the role of the PET imaging in the management of NET.

11:40 -12:00

Release of Patients After Radionuclide

Therapy

Mr. Nabil IqeilanMedical Physicist

Chairman of Education And

Training Mefomp Hamad Medical

Corporation.

- Discuss regulations regarding releasing of patients after radionuclide therapies.- Understand the contribution of medical physicist in measuring exposures and implementing proper practice.

12:00 -13:30 LUNCH BREAK & FRIDAY PRAYER


43

Session 11: Theranostics in Prostate Cancer

Chairpersons:A/Prof. Hossein Jadvar (USA)Dr. Suhad Mneir (Jordan) Mr. Ibraheem Habashneh (Jordan)


13:30 - 13:55

Role of PSMA in Diagnosis and Therapeutic of

Prostate Cancer; Lebanese

Experience

A/Prof. Mohamad Haidar

Director of Nuclear

Medicine Division,

PET/CT and Cyclotron

Facilities

Associate Professor,

Diagnostic Radiology

Department

American University

of Beirut Medical

Center.

- Understand the role of PSMA PET

in diagnosis of primary prostate

cancer.

- Recognize the value of PSMA

PET in biochemical relapse

summarize the potentials of PLRT.

13:55 -14:20PSMA Pitfalls and

Artifacts

Prof. Medhat Osman

Professor of Radiology

Director of Nuclear

Medicine & PET/CT

Nuclear Medicine

Training Program

Director

Saint Louis University,

USA.

- Review the PSMA PET/CT

procedure.

- Illustrate the causes of artifacts in

PSMA PET/CT.

- Demonstrate the potential

pitfalls may be encountered in

PSMA PET/CT.


44

14:20 -14:50

State-Of-The-Art PSMA-Targeted

PRLT 2.0 - Individualized Treatment and Augmentation

Approaches

Prof. Samer Ezziddin

Director & Professor of Nuclear

Medicine at Saarland

University, Germany.

- Understanding the mechanism and specifics of PSMA-targeted PRLT. - Understanding potential risk factors for a worsened course of disease under therapy. - Indications for PRLT and arguments for earlier application. - Contraindications and pseudo-contraindications. - When to escalate PRLT. - Augmentation methods for PRLT. - CO-medication and potential maintenance therapy in PRLT responders. - Toxicity profile of lu177 and ac225 based PSMA-targeted PRLT.

14:50 -15:10

Prostate Cancer New Diagnostic and Treatment Options Using Ready to use

Kits(Or Kit Similar Assembling's)

Mr. Stephan MausRadiochemist, at

Saarland University, Germany.

- Obtain information about prostate cancer statistics. - Learn something about the anatomy of different PSMA bio-conjugates. - Will be familiar with the effect of kit design for the radioactive labelling with different nuclides. - Understand the benefits of the kit labelling procedure and could integrate the concept into clinical routine.



45

Session 12: Research Paper & Regional NM Activities & Highlight Lecture

Chairpersons:A/Prof. Akram Al-Ibraheem (Jordan, JOSNM & ARSNM)Dr. Amjad Albader (Iraq, ARSNM) Dr. Majdi Zein (Syria)


15:30 -15:50 Research From a Question to a

Paper

Dr. Naima Khamis Al-Bulushi

Director of Nuclear Medicine Department

at Royal Hospital in Oman

- A demonstrate the importance of

research in today’s evidence based

clinical practice.

- Discuss the different types of

studies that can be done and their

main components.

- Recognize the importance of copy

writes and plagiarism

- Recognize the structure and

components of a good research

versus a weak one.

15:50 -16:10Nuclear Medicine

in Algeria

Dr. M.Yahiaoui Algerian Association

of Liberal Nuclear Medicine Practitioners

- Demonstrate the current situation

of nuclear medicine in Algeria.

- Discuss the changes and

opportunities of nuclear medicine

in Algeria.


46

16:10 -16:30Current Status of Nuclear Medicine

in Morocco

Dr. Hind Aschawa

President of Moroccan Society of

Nuclear Medicine.

- Demonstrate the current situation of nuclear medicine in morocco . - Discuss the changes and opportunities of nuclear medicine in morocco.

16:30 -17:00Highlight Lecture

and Closing Ceremony

A/Prof. Khaled Alkhawaldeh & Prof. Abedalatif

AlSharifHead of Nuclear

Medicine Dept. - Royal Medical Services &

Professor at the Department of Radiology and

Nuclear Medicine/ University of Jordan. Medical director at Afia radiotherapy

and Nuclear Medicine Center


47

Abstracts


48

SUV max cut-off between aggressive and indolent non-Hodgkin lymphoma in non-time of flight 18F- FDG PET/CT and time of flight  18F-FDG PET/CT

Name : Specialist Country Email

Galal Alobthani Dr. / Nuclear Medicine

Japan [email protected]

Galal Al-Obthani1 , Victor Romanov ,  Kayako Isohashi ,  Keiko Matsunaga  , Tadashi Watabe ,  Hiroki Kato, Mitsuaki Tatsumi ,  Eku Shimosegawa, Jun Hatazawa

Department of Nuclear Medicine and Tracer kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, Japan

Abstract Purpose: Non-Hodgkin’s lymphoma (NHL) cases with inconclusive biopsy findings are not infrequently referred for fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). We searched for maximum standardized uptake value (SUV max) cut-off values that could discriminate between indolent and aggressive NHL in conventional non-time of flight (non-TOF) 18F-FDG PET/CT and TOF 18F-FDG PET/CT.

Methods: Retrospectively, 328 patients were selected by the following inclusion criteria: biopsy-proven NHL with no more than one histopathological type; new cases with less than 90 days between obtaining biopsy and 18F-FDG PET/CT scanning; recurrent cases with time interval more than six months since the last therapy with no history of transformation; and blood glucose less than 150mg/dL. Two hundred forty six (246) selected patients were scanned with non-TOF PET/CT, and 82 patients were scanned with TOF 18F-FDG PET/CT.

Results: The SUV max of NHL tends to be higher in TOF 18F-FDG PET/CT than non-TOF 18F-FDG PET/CT. New aggressive NHL had significantly higher SUV max than new indolent NHL in both, non-TOF 18F-FDG PET/CT (13.6 ± 7.7 vs. 5.3 ± 3.4 g/mL, P<0.0001) and TOF 18F-FDG PET/CT (20.5 ± 9.8 g/mL vs. 6.6 ± 4.7 g/mL, P<0.0001). A receiver operating characteristic curve analysis for new cases in non-TOF 18F-FDG PET/CT (n=204), demonstrated SUV max of 10g/mL as the most balanced cut-off  between aggressive and indolent NHL, with the area under the curve (AUC) of 86%, specificity of 94%, and sensitivity of 71%. While SUV max of 13g/mL was the most balanced cut-off for new cases in TOF 18F-FDG PET/CT (n=57), with AUC of 91%, specificity of 95.5%, and sensitivity of 77%.

Conclusion: SUV max>10 in non-TOF 18F-FDG PET/CT and > 13 in TOF 18F-FDG PET/CT were highly suggestive of an aggressive nature of NHL, while there was an overlap between indolent and aggressive NHL in the lower SUV max levels.

Abstract1


49

Radiotherapy-induced structural and functional changes in the thyroid gland


Mai Elzahry Egypt [email protected]

Mai Elzahry1* , MD, P.hD Mohamed Wahman1 , MD, Ph.D

Department of Clinical Oncology & Nuclear Medcine, South Valley University,Qena, 83523, Egypt.

Abstract Background: Despite their specific functional consequences, radiotherapy (RT) induced thyroid disorders remain under evaluated, even though, various types of radiation induced benign, malignant structural and functional diseases of the thyroid cancers have been reported in this study.

Objective: to evaluate the current evidence concerning the effects of various types of radiation on the development of benign, malignant structural and functional diseases of the thyroid. Materials and Methods: This is a retrospective clinical study on 40 cancer patients treated with radiotherapy at the Department of Clinical Oncology & Nuclear Medicine, South valley University, Qena, Egypt between July 2011 and July 2016. 14(35%) males and 26(65% females, their age range (33-80y, means=56.5±11.8). After the completion of treatment, all patients were seen at 6 weeks then every 4–6 months for first 5 years. For the purpose of the study, full thyroid gland assessment was performed (clinical examination, lab investigations, thyroid U.S and Fine Needle Aspiration Cytology (FNAC) for malignant Thyroid. Results: After full clinical and anatomical assessment of the thyroid gland abnormalities in all 40 cancer patients received a variable doses of radiotherapy referred to the Clinical Oncology and Nuclear Medicine Department, we found that 40% of the patients showed multinodular goiter by thyroid U/S with normal hormonal profile, 22.5% showed thyroiditis presented by hypothyroid symptomes confirmed by low T3 and T4, elevated TSH with high level antithyroid antibodies and 37.5% showed differentiated cancer thyroid (25% papillary,12.5% follicular cancer) assessed initially by U/S proved later by FNAC from the gland. The incidence of malignant thyroid diseases increased significantly among the older patients received high radiation doses(>50Gy) over long post-therapy follow up. Conclusion: Numerous thyroid disorders may develop following irradiation to the thyroid gland. Little is known about the true incidence and the etiology and risk factors of these disorders. Patients age and high radiation dose(>50Gy) play an important role in the occurrence of malignant thyroid diseases. Further prospective studies with large sample size are warranted in order to understand better the dose-effect and to reduce the incidence of radiotherapy-induced thyroid dysfunction. Keywords: Radiotherapy, benign & malignant structural changes, thyroid gland Radiotherapy-induced structural and functional changes in the thyroid gland

Abstract2


50

Dual time point F-18 FDG PET/CT in differentiation between malignant and benign lesions in cancer patients.

Name : Specialist Country Email Hussein Rabie Nuclear Medicine Specialist Saudi Arabia [email protected] +96656596

4294

Hussein Farghaly, Abdulla Alqarni, Hatem Ahmed Nasr Department of Radiology, Division of Nuclear Medicine, Prince Sultan Military Medical City, Riyadh,

Saudi Arabia PURPOSE: Assess the added value of DTP 18F-FDG-PET/CT in differentiation malignant (M) from benign (B) lesion in cancer patients. METHODS: 140 F-18- FDG PET/CT scans of 60 cancer patients with suspicious FDG avid lesion and DTP protocol (whole body PET/CT at 60 min. (E) and delayed (D) limited PET/CT on areas of interest at 120 min. after the tracer injection) were retrospectively reviewed. Visual and semiquantitative analysis was performed on both early and delayed images. All findings were confirmed by histopathology and/or at least 3 months follow-up (PET CT, CT, MRI). The result consider true positive (TP) in lesions with increased SUV in delayed image and confirmed to be M, false positive (FP) if increased SUV and confirmed to be B, true negative (TN) if decreased or unchanged SUV and confirmed to be B and false negative (FN) if decreased SUV and confirmed to be M. RESULTS 164 suspicious lesions detected (the common, were 20 presacral lesions, 18 lung nodules,16 rectal lesions, 18 Hodgkin’s disease (HD) lesions, 16 head and neck (H&N) lesions, 14 hepatic lesions and 14Non-Hodgkin’s lymphoma (NHL) lesions). 64 lesions were pathologically confirmed and 1000 lesions confirmed based on 3 -6 months follow-up. There were 62 TP lesions, 44 FP, 58 TN and no FN results. The overall sensitivity was 100% of DTP FDG PET/CT in detecting suspicious lesions. The specificity was 57% in differentiating M from B lesions and the accuracy was 73%. PPV was 59%, NPV 100%. All hepatic lesions were TP. Accuracy in metastatic hepatic lesions, HD, presacral soft tissue, lung nodules, H&N cancer, breast cancer, NHL and mediastinal LN was100%, 88.8%, 80%, 78%, 75%, 75%, 71% and 33.3% respectively. The number of FDG avid lesions increased in delayed images in 8 , 4 and 4 patients with HD, NHL and hepatic metastasis respectively.

CONCLUSIONS

DTP 18F-FDG-PET/CT protocol is not always working. However; promising results was noted in hepatic lesions, lymphoma and recurrent rectal cancer with high NPV, Further studies with large patient number and more quantitative parameters are need to emphasize these results

Abstract3


51

Heterogeneous vs homogeneous tumors detection and segmentation in PET


Dr. Hadi Fayad Medical Physicist

Egypt [email protected]

Dr. Hadi Fayad 1- OHS, PET/CT Center, Hamad Medical Corporation, Doha, Qatar

Abstract Purpose: Accurate delineation of metabolically active tumor volumes (MATV) in PET imaging is a challenging task, mainly due to low spatial Resolution and strong levels of noise. In a previous study, we developed a segmentation approach based on Ant Colony Optimization (ACO), a Population-based model that mimics the collective foraging behavior of real ant colonies. The objective of this study will be focused on extending the ACO model to the detection of homogeneous and heterogeneous

Tumors as well as the segmentation of such tumors. Methods: Artificial ants explore their environment (PET image) in quest for food (MATV) and exchange information through iterative pheromone update, attracting other ants along their path. Unlike global thresholding algorithms, we exploit local neighborhood analysis to enhance the spatial consistency of the final volume. At convergence, a pheromone map is obtained with highest density around the MATV. The developed ACO algorithm was tested on a 6 real based tumors simulated dataset including different levels of heterogeneities and noise. It was also compared to Fuzzy Locally Adaptive Bayesian (FLAB) algorithm which is one of the reference method in PET heterogeneous image segmentation. Results: ACO algorithm can detect homogeneous and heterogeneous tumor with an 100% accuracy. Our results were also promising since the segmented images were close to the ground truth with a mean percentage error of 4.4 ± 3% compared to flab with an error of 6.3 ±5.7%

Conclusion and perspectives: We developed a promising method for the detection of homogeneous and heterogeneous tumors as well as their segmentation. Future development will include parameter optimization and automatic estimation of food source to further extend the robustness of the method as well as the use of this algorithm for other applications such as the estimation of 4D PET Kinetics parameters of physiological significance.

Abstract4


52

Investigating the diagnostic accuracy of CT, 18F-FDG PET/CT and EBUS/TBNA in preoperative mediastinal nodal staging of NSCLC


Ula Al-Rasheed, Nader Hirmas, Akram Al-Ibraheem

Nuclear Medicine specialist

Jordan [email protected]

Ula Al-Rasheed, Nader Hirmas, Akram Al-Ibraheem King Hussein Cancer Center

Abstract

Background: Staging of non-small-cell lung cancer (NSCLC) is a multidisciplinary process involving imaging, endoscopic and surgical techniques. This retrospective cohort study aims at investigating the diagnostic accuracy of 18F-FDG PET/CT, CT scan and endobronchial ultrasound/transbronchial needle aspirate (EBUS/TBNA) in preoperative MLN staging of NSCLC in comparison to mediastinoscopy and histopathologic diagnosis.

Methods: We identified all patients who were diagnosed with NSCLC at the King Hussein Cancer Center in Amman, Jordan, between July 2010 and December 2017. We collected their relevant clinical, radiological and histopathological findings. Per-patient analysis was performed on all patients (N=101) and then on those with histopathological confirmation (N=57), followed by a per-lymph-node-station basis overall, and then according to distinct N-stage categories (N0, N1 and N2/3). Results: 18F-FDG PET/CT supersedes the sensitivity, specificity, PPV, NPV and accuracy of CT scan in MLN staging, with slightly lower accuracy compared to mediastinoscopy and EBUS/TBNA, and comparable NPV to the latter modalities. Dividing patients into N1 disease vs. those with N2/N3 disease yielded similar findings. Comparison between 18F-FDG PET/CT and EBUS/TBNA in patients with histopathological confirmation shows 28 correlated true positive and negative findings. In four patients, 18F-FDG PET/CT detected metastatic MLNs that would have otherwise remained undiscovered by EBUS/TBNA alone. On the other hand, EBUS/TBNA conferred accurate staging in one patient who had positive sub-carinal LN TBNA result which was missed by 18F-FDG PET/CT. Finally, EBUS/TBNA showed true negative findings in six cases that were deemed false positive by 18F-FDG PET/CT.

Conclusion: 18F-FDG PET/CT surpasses EBUS/TBNA in excluding MLN metastases in NSCLC, has better overall diagnostic utility than CT scan, and has comparable NPV to mediastinoscopy. Positive 18F-FDG PET/CT MLNs, particularly if such a result would change treatment decisions and outcomes, should be verified histopathologically.

Abstract5


53

APPLICATION OF RENAL SCINTIGRAPHY TO ASSESS THE EFFECT OF HYPOTHYROIDISM ON KIDNEYS

Name : Specialist Country Email SYEDA AYESHA AMMAR BOKHARI

NUCLEAR PHYSICIAN

PAKISTAN [email protected]

AMMAR.A, SAEED. M.A, FATIMA.S, MIR.K, BUTT.S, SYED.M, FAHEEM. M NORI Hospital, Islamabad.

Abstract INTRODUCTION: The present study is planned to see the hypothyroid effects on renal function using GFR value as a marker of renal function.

AIMS AND OBJECTIVES: To study the effect of hypothyroidism on renal function using camera based GFR assessment method.

MATERIAL AND METHODS: Total number of 58 patients were included in the study. Out of 58 patients, 53 patients were of Ca-Thyroid in whom hypothyroidism was due to discontinuation of thyroxine (51 patients) or injection of recombinant TSH (2 patients). Moreover, remaining 5 patients were post Radioactive iodine treatment (for hyperthyroidism) hypothyroid. Renal function tests (urea/creatinine) and serum electrolytes followed by Tc-99m- DTPA renal scan for GFR assessment (GATES’ method) were carried out in all subjects twice during the study -- One study during hypothyroid state (TSH > 30mIu/ml) and other during euthyroid state (TSH between 0.4 to 4 iU/ml). In addition, renal function was assessed with creatinine clearance in those subjects who showed raised creatinine values in either of study (Hypothyroid or euthyroid state). RESULTS: The results of Student’s t-test showed significant difference in renal functions (Urea, creatinine, creatinine clearance, GFR values) in euthyroid state and hypothyroid state (p-value <0.05).In case of creatinine the paired t test reveal the mean 1.014±0.428, with standard error of 0.669 with in 95% confidence interval, for creatinine clearance 80.11±14.12 with standard error of 1.94 with in 95% confidence intervals, for urea the mean 28±12.13 with standard error of 1.607 with in 95% confidence intervals and for gfr for individual kidney is 38.056±8.56 with standard error of 1.3717 with in 95% confidence interval.

CONCLUSION: Hypothryoidism, irrespective of the cause, impairs renal function to a significant level and hence needs to be prevented and corrected as early as possible.

Abstract6


54

Abstract 7

Place of FDG PET in melanomas : case study

Name : Specialist Country Email GUENSI AMAL Nuclear

medicine Specialist

Morocco [email protected]

A. OUBOUKDIR, Z. OUASSAFRAR, S. NADI, S. TALEB, A. GUENSINuclear medicine department – Ibn Rochd hospital Casablanca

Background : Melanoma is the rarest skin cancer (5% all skin cancers), but he is the one with the most poor prognosis, Positron-emission tomography/computed tomography (PET/CT) is a unique imaging tool that aids in the staging, the extension assessment and the follow up. Here we report our findings of different lesions discovered during PET/CT staging of patients with melanomas.

Material and methods : We performed a retrospective case review of 92 patients having histologically proven melanomas. Patients with metastases at the time of examination (known melanoma or other previously treated neoplasia) were excluded; patients who have received recent anti-cancer treatment (surgery or Chemotherapy) and patients with uncontrollable hyperglycemia before the examination. FDG PET/CT scan reports in the department of nuclear medicine of the university hospital of Casablanca between 2014 and 2018 were reviewed, The data from all reports were analyzed for the age, the sexe, the indication, the initial location of the melanoma, loco-regional nodal disease and distant metastasis.

Results : ninety-two patients were included in the study, the average age of our patients was 55.06 ; the sex ratio 0.93 The initial locations of melanomas were divided as follows: forty-eight limb locations (52%, 14% upper limb and 38% lower limb); twelve cervicofacial locations (13%), twenty one mucosal locations (23%) and eleven ganglion lesions of an unknown primitive melanoma (12%). PET-CT scanning was performed as part of the extension assessment in 65% of cases; suspicion of Recurrence in 23% of cases or post-treatment evaluation in 12% of cases. Primary tumors were detected in 62% of patients referred for initial extension assessment. Hypermetabolic lesions on the affected limb were found in 17% of cases suggestive of skip metastases. Locoregional lymph node extension was found in 48% of cases. hypermetabolic lung lesions were found in four patients and hypermetabolic liver lesion in one patient.

In patients suspected of recurrence, the examination revealed a local progressive disease recovery in 7% of cases. Locoregional ganglion lesions hypermetabolic in 64% of cases. And distant hypermetabolic lesions in 69% of cases (lung, liver and bone).

Abstract7


55

For patients referred for post-treatment evaluation, 71% had suspected local recurrence; 56% had suspicious ganglion lesions and 42% had secondary remotely located lesions (lung and liver). For patients referred for lymph node involvement of unknown primitive, exploration revealed hypermetabolic skin lesions in five of the eleven cases. The examination did not reveal hypermetabolic lesions suspected of secondary localization or recurrence in 1% of cases.

Discussion and conclusions : The management of melanoma has changed with the development of new imaging modalities particularly the PET/CT, it has a high sensitivity and specificity for detection of distant metastatic disease from malignant melanoma. PET/CT remains useful for assessing disease extension, especially in stage III and IV melanomas (with nodal or metastatic involvement), in case of proven or suspected recurrent disease, it can guide therapeutic strategy, by directing the patient to a local treatment in case of loco-regional disease, or a systemic treatment in case of metastatic disease. PET/CT may also have a part in therapeutic evaluation, even if it is still not fully codified. Patients with melanoma are at risk for development of recurrence and metastases, FDG-PET/CT is superior to CT for detection of recurrence in the surveillance setting but the impact and cost- effectiveness of surveillance imaging in patients with melanoma has yet to be determined.


56

Abstract 9

Predictive factors of node metastasis for Well-differentiated thyroid carcinomas

Name : Specialist Country Email Sara Taleb: Nuclear

medicine Specialist


S. Taleb, G. Cherkaoui Salhi, S. Nadi, S. Zouine, A. Guensi

Nuclear medicine department – Ibn Rochd hospital Casablanca

Introduction: Lymph node disease is one the most important prognosis factors in patients with well- differentiated thyroid carcinomas (WDTC) by increasing recurrence and mortality risks. The aim of this study is to highlight node metastasis (NM) predictive factors of in patients WDTC. Methods: A multicentric retrospective study enrolling all cases of WDTC with NM confirmed histologically and treated by radioiodine therapy in Ibn Rochd university hospital in Casablanca- Morocco from January to December 2017. Multivariate and χ2 analyses were used comparing epidemiological, clinical and histological factors of patients with NM (group I) with population with no node metastasis (group II).

Results: The study included 33 patients from 434 WDTC (7%). Average age was 48 years old ( ± 16),= sex ratio (F/M): 5. Tumours were rated T1 in 54% of cases, T2 in 18% of and T3 in 28%. The main predictive factors of NM were tumour capsular invasion (p < 0.001), vascular invasion (p < 0.001) and locally advanced tumour (p = 0.001). Conclusion: These data are in agreement with those of the literature. Patients should be selected for more aggressive therapeutic treatment.

Abstract8


57

18 FDG PET/CT in cutaneous melanoma : experience of nuclear medicine

Name : Specialist Country Email Sara Taleb nuclear

medecine phycisien

Morocco guensiamal@@gmail.com

S. Taleb, G. Cherkaoui Salhi, A. Ouboukdir, Z. Ouassafrar, A. Guensi

Nuclear medicine department – Ibn Rochd hospital Casablanca

ABSTRACT : The aim of this study is to describe lesions features found in 18FDG PET/CT in patients with CM. Eighty patients with CM were sent to nuclear medicine department of Ibn Rochd university hospital between January 2014 and December 2017. Inital tumour was located in the limbs (75% of cases), and the cervicofacial region (25% of cases). Among patients sent for initial staging: initial tumour was FDG avide in all cases. PET/CT didn’t show any abnormality in 25%, it revealed high uptake in regional lymph nodes in 41% and distant high uptake in 8% of cases. A skip metastases was found in 25% of cases. In patients with recurrence suspicion, PET/CT was positive in all cases. It showed a local recurrence for all patients, with high uptake in regional lymph nodes in 25% of cases, and nodal and distant high uptake (metastases) in 50% of cases. The exploration showed also a high nodal uptake without local uptake in 25% of case. In patients sent for end of treatment assessement ; 75% of cases showed a local and regional lymph node uptake, among them 50% showed distant metastasis. In on case, PET/CT did not reveal any abnormal hypermetabolism. Currently, FDG PET/CT allows a more accurate cartography of CM lesions. It also allows a better treatment response assessement with classic and new treatment.

Abstract9


58

GFR calculation on DTPA renal scan: comparison between using soft ware’s auto renal depth vs actual depth from ultrasound and its correlation with e GFR

Name : Specialist Country Email Dr Farzeen Zehra Nuclear

Medicine Specialist

Pakistan [email protected]

Dr Farzeen Z, Dr Saif H, Dr Sadaf B, Dr Ayesha A, Dr Adnan S, Dr Kahkashan B, Dr Shazia F, Dr M Faheem

Inmol Cancer Hospital oncologists

Purpose: Increasing prevalence of chronic kidney disease with aging population necessitates evaluation of renal function in clinical practice. Glomerular filtration rate (GFR) is useful for evaluating renal function. Currently, renal dynamic imaging is widely adopted to gauge GFR. Several factors can affect GFR estimation, renal depth is one of them. GFR is measured using Gates Method and automated kidney depth to estimate renal depth in individual that utilizes anthropometric data gathered from other populations. This formula gives variable values for GFR. In routine clinical nuclear medicine practice, actual kidney depth is not used. The purpose of this study is to identify patients where measuring kidney depth is of clinical significance and effects GFR values to an extent as to formulate the management outcome. Material and method: A total of 150 patients were included in study. Kidney depth was measured using ultrasound probe. After DTPA renal scan was done using standard study protocol, GFR was calculated by Gates’ method using auto kidney depth by software and then by actual kidney depth. eGFR of patient was calculated by calculators online. Two sets of data comprising of calculated GFR of same patient by two methods and their correlation with each other and with eGFR was analyzed by ‘paired student t test’, results were obtained at p value of 0.005. Results: GFR obtained in patients with BSA that was within 0.8 (m^2) of the reference BSA was well calculated by using auto kidney depth while in patients with BSA more than 0.8 (m^2) deviated, soft ware calculated GFR was significantly different from GFR calculated by using actual kidney depth. GFR calculated with actual kidney depth correlated more with eGFR in comparison to the GFR from auto kidney depth method. Conclusion: GFR calculated with actual kidney depth is more reliable still for routine practices, auto kidney depth used by soft ware is fairly useful but in cases where BSA deviates from reference BSA significantly, actual kidney depth is useful. When GFR serial monitoring is critical, GFR calculated with actual kidney depth is more reliable. In selected patients actual kidney depth should be used to calculate GFR.

Abstract10


59

18FDG PET/CT imaging in plasmocytoma: a case report and review of the literature

Name : Specialist Country Email Nadi Samira Nuclear

Medicine Specialist


S. Nadi, S. Zouine, A.Ouboukdir, G.Cherkaoui Salhi A. GuensiNuclear Medicine Department, Ibn Rochd University Hospital,

Université Hassan II, Casablanca, Morocco Abstract: Background: The solitary plasmocytoma (SP) accounts for 5 to 10% of plasmocytic malignant dysglobulinemias. Its diagnosis is based on histological evidence of clonal plasma cell proliferation, without evidence of systemic disease, and is a unique localized, bony or extraosseous disease. However, the disease can be diffuse and up to 5% of patients with a solitary plasmocytoma develop multiple subclinical lesions without having the criteria of myeloma or multiple myeloma in more than 50%. The prognosis depends on its progression to multiple myeloma, which requires regular follow-up.

Objectives: to illustrate the usefulness of 18 FDG PET / CT in the diagnostic of the plasmocytoma.

Médical observation: A 66-year-old man ,with no medical history, presenting hyperalgic dorso-lumbalgia, the serum immunofixation showed a hypergammaglobulinemia of polyclonal appearance evoking an inflammatory syndrome, the myelogram showed poor cellularity.The bone scan demonstrated a heterogeneity of the dorsolumbar spine with low focal uptake in T12 surrounded by high uptake . Medullar MRI showed vertebral compression of T12 with spinal cord compression and T2 and S1 corporal nodular lesions. The patient had a surgical biopsy of the T12 lesion. Histological and immunohistochemical examination concluded vertebral plasmacytoma with Kappa monotypy. The patient was then referred to the nuclear medicine department for 18 FDG PET / CT.

Results: After 6 hour of fasting, the patient was injected with 5 MBq /kg of 18FDG. An hour later, the patient underwent an acquisition of images mid-skull, mid-thigh (7 steps) of CT then PET. Images showed a high uptake in the lytic lesion of T12 (SUVmax at 5.5), with no other abnormal uptake except unilateral hilar pulmonary mediastinal adenopathy (SUVmax at 4.3).

Conclusion: This case report illustrates the high uptake of solitary plasmocytoma with the advantage to explore bone and extraosseous sites

Abstract11


60

Abstract 14

Usefulness of 18 FDG PET/CT scan in the management of pure testicular seminoma

Name : Specialist Country Email Nadi Samira Nuclear

Medicine Specialist


S. Nadi, S. Zouine, Z.Ouassafrar.S.Taleb, A. GuensiNuclear Medicine Department, Ibn Rochd University Hospital,

Université Hassan II, Casablanca, Morocco Abstract: Background: Malignant testicular tumours are in 98% of cases germ tumors (TG) distributed in pure seminoma (SGT) in 55% and non-seminomatose tumor (NSGT) in 45% of cases. SGT occur in men between 30 and 35 years. It gives pulmonary, hepatic or cerebral metastases. SGT are very sensitive to chemotherapy. The precise assessment of initial extension and the early diagnosis of recurrences impact the prognosis.

Objectives: This work reports the usefulness of the 18FDG TEP/TDM in the management of SGT.

Materials and methods: between April 2017 and April 2018, eight 18FDG PET/CT scan were carried out in 4 patients followed for SGT testicular for an extension study (3 exams, initial extension assessment (2) and restaging (1)), an evaluation of the treatment response (3 exams), and a residual masscharacterization (2 exams).

Results: These are 4 men with, an average age of 36 years (from 25 to 45 years). The results of PET/CT scan were: for the extension assessment, the primitive tumor was visible in one patient, it was an ectopic right testicular located in retroperitoneal, the SUV max was 4.3. The other two patients had positive lymph nodes: inguinal bilaterally and primitive iliac in one case, and one abdominal in the other. PET did not show any metastatic extension in all 3 cases. The post-therapeutic evaluation 18FDG PET/CT scan showed a complete metabolic response in 1 case, a partial response in 1 case and a progressive disease in the third. For the residual mass characterization the 18FDG PET/CT scan showed a mass stretching from the retro-pancreatic space to the aortic bifurcation without hyper metabolism. This result was confirmed 6 months later on a monitoring 18FDG PET/CT with total regression of the mass.

Conclusion: The initial extension assessment of the SGT is done by a conventional morphological exam without need to 18FDG PET/CT scan. However, 18FDG PET/CT scan becomes very useful in restaging after recurrence and even more useful for post-therapeutic evaluation. Indeed in the characterization of residual masses in order to differentiate viable tumors requiring a therapeutic consolidation of fibrous masses..

Abstract12


61

Abstract 15

Role of FDG hybrid imaging in detection of recurrent renal cell carcinoma and its correlation with histopathological variant

Name : Specialist Country Email Aftab Hasan Nazar Nuclear Medicine India [email protected]

Aftab Hasan Nazar Purpose:

Role of FDG hybrid imaging in detection of recurrent renal cell carcinoma and its correlation with histopathological variants.

Method:

Normoglycemic patients of renal cell carcinoma were injected with 8mCi of F-18 FDG from and were imaged with Siemens PET CT camera. The data was processed and evaluated by minimum of two nuclear medicine physicians. The scan were done over the period of Jan 2018 to 31 May 2018. The relationship of the SUV max of the lesion with histological variants were anylysed.

Result:

For renal malignancies, this study tries to find any relation between the histological variants of primary and metastases as found on F-18 FDG PET CT. We have 15, 04, 03, patients of clear cell, papillary and sarcomatoid variants respectively. For clear cell variant the most common sites of metastases were mediastinum (SUVmax range 2.04-8.09) and abdominal & retroperitoneal lymph nodes (SUVmax range 2.8-18.5). Liver metastases were found in two patients (SUVmax 17.9 and 5.82). For papillary variant, a high FDG avidity was noted for the primary lesion (SUVmax 13.69 and 3.7). The sarcomatoid variant of renal cell carcinoma, further high FDG avidity was noted in the primary lesion (SUV max 37.3 and 13.42). In addition, we also had follow up of 8 patients. Out of which one patient had 3 follow up scans and 4 patients had 3 follow up and 3 patients had two follow up. Out of these two patients had residual at the primary site, five had mediastinal and four had abdominal metastases as detected on follow up. Also, there were 3 patients with lung metastases and five patients with skeletal metastases. Conclusion:

F-18 FDG PET CT shows metabolically active disease and is widely used for diagnosis and follow up ofpatients of renal cell cancer. F-18 FDG PET CT using SUV max may have a significant role in follow up and change in management. It also has remarkable in impact in overall staging.

Key words: Renal cell carcinoma, F-18 FDG PET CT, SUVmax, Staging.

Abstract14


62

Abstract 15

The value of FDG PET CT in the assessment of patients with Renal Cell carcinoma

Name : Specialist Country Email ABDELBASET ALRAWASHDEH

Nuclear Medicine JORDAN [email protected]

ABDELBASET ALRAWASHDEH Jordanian royal medical services, Nuclear Medicine Center

AIM: The aim of this study is to assess the value of FDG PET-CT in detecting local recurrence or distant metastases in patient with renal cell carcinoma.

METHODS: A number of 45 patients with known case of renal cell carcinoma who underwent radical or partial nephrectomy were included in this retrospective study.All patients underwent diagnostic CT-Scan and PET-CT after surgery in different occasions for follow up.

RESULTS: PET-CT was positive for malignancy in 37 patients compared to 22 cases for CT scan. PET CT revealed sensitivity, specificity and accuracy of 94%, 90% and 92% Respectively compared to 72%, 62% and65 % For CT.

CONCLUSION: PET-CT scan is the modality of choice for follow up of patients with RCC , with improved accuracy compared to CT scan. Change in patients management can be expected in considerable number of patients.

Abstract15


63

Abstract16

Correlation of Prostate Specific Antigen with Metastatic Bone Disease in Prostate Cancer on Ga-68 PSMA PET/CT Scan.

Name : Specialist Country Email Muhammad Waleed Asfandyar,

Nuclear Medicine specialist

Pakistan [email protected]

Rashid-ul-Amin, Abdul Hai, Inam Hiader, Adeel Rasheed,

Syed Adib-ul-Hasan Rizvi Sindh Institute of Urology and Transplantation, Department of PET/CT & Molecular Imaging.

Objectives: To define the correlation between serum PSA levels and Ga-68 PSMA in the prostatic cancer

patients.

Methods: Relationship between serum PSA kinetics with metastatic prostate cancer on Ga-68 PSMA

PET/CT for staging/restaging for prostatic carcinoma in Sindh Institute of urology and transplantation,

Department of molecular imaging were evaluated retrospectively.

Results: Totally 29 patients included in the analysis. Mean age of patients was calculated as 68.2±7.6

(min-max: 51-88) years old.Ga-68 PSMA PET/CT indications were staging, restaging and response to

treatment. Cut-off serum PSA level to predict Ga-68 PSMA PET positivity was calculated as 2.5.We

calculated Serum PSA levels and Ga-68 PSMA positive and negative groups according to specified

ranges i.e >10 PSA the PPV was 60% vs NPV 40%.<10 PSA the PPV was 38.4% vs NPV 61.5%, > 5

PSA the PPV was 52.9% vs NPV 47.0%. < 5 PSA PPV was 54.5% vs NPV 45.4%, >2.5 PSA, PPV was

32.5% vs NPV was 37.5%. <2.5 PSA, PPV was 47.8% and NPV was 52.1 % respectively.

Abstract16


64

Conclusion: Serum PSA levels seems to correlate with Ga-68 PSMA PET/CT. Patients with PSA levels

even less than 2.5 ng/ml would probably positive on Ga-68 PSMA PET/CT. In order to detect recurrent

or metastatic disease at earlier stages more sensitive methods needed. After reviewing published articles

of skeletal Scintigraphy with Tc-99m MDP we found that the serum PSA cutoff was 10ng/ml, while in

our study with Ga-68 PSMA we found that even at low PSA i.e <2.5 ng/ml, the positive predictive value

was 47.8%. Ga-68 PSMA PET/CT is much more sensitive and specific as compared to other imaging

modalities to investigate metastatic disease of prostate cancer.

PLATINUM SPONSOR


65

Sponsors

PLATINUM SPONSOR


66

GOLDEN SPONSOR SILVER SPONSORS


67

GOLDEN SPONSOR SILVER SPONSORS


68

GENERAL INFORMATION

Venue : Landmark Hotel - Amman - Jordan.

Language : English is the official language of the conference.

Airline : Royal Jordanian.

Currency : Jordanian Dinar (JD). Please note that 1.00 USD is equivalent to 0.7 JD.

Weather : for weather information please visit : www.jometeo.gov.jo

ACCOMMODATIONLandmark Hotel : (5 stars )

SGL Room : 100 USD bed & breakfast

DBL Room : 115 USD bed & breakfast

- All Above rates are per night per room.

- All above rates are subject to 10% service charge & 16% tax.

REGISTRATION REGISTRATION FEES

Physicians US$ 200

Member of JOSNM & ARSNM US$ 100

Radiopharmacist & Physicists & Technologist US$ 100

Residents, Med Student Free Entry to scientific sessions only

One-day Registration USD 50

The Conference has been accredited by :- The European Accreditation Council for Continuing Medical Education (EACCME®) with 17 Europe-an CME credits (ECMEC®s)

- The Jordanian Medical Council with 17 CME credits.

Co�ee Break

Co�ee Break

EXHIBITION FLOOR PLANVENUE HALL : -1

ENTREN

CE

B1-Platinum B2-Silver

B6-Golden B7-Silver B8-Silver B9-Silver B10

B3-Silver B4

B11

B5


69

Co�ee Break

Co�ee Break

EXHIBITION FLOOR PLANVENUE HALL : -1

ENTREN

CE

B1-Platinum B2-Silver

B6-Golden B7-Silver B8-Silver B9-Silver B10

B3-Silver B4

B11

B5

Booth NumberSponsership LevelCompany Name

B1PlatinumFirst National Medical Service

B6GoldAl Faisaliah Healthcare Systems (FHS)

B2SilverJaber Medical Supplies Est.

B3SilverTRASIS

B7SilverBiodex

B9SilverTEMA SINERGIE

B8SilverSumitomo Heavy Industries

B5ExhibitorCyclomedical

B10ExhibitorMEFOMP

B4ExhibitorLEVALIS Pharma SAL

SPONSORS AND EXHIBITORS


70

EXHIBITION TIME SCHEDULE

SET-UP: Tuesday, 28th . Aug 16:00 - 23:00

EXHIBITION OPENING HOURS: Wednesday, Aug. 29th 09:00 – 17:00

Thursday, Aug. 30th 09:00 – 17:00

Friday, Aug. 31st 09:00 – 17:00

DISMANTLINGFriday, Aug. 31st 17:00– 23:00

REGISTRATION DESK & CONFERENCE DESK

OPENING TIMES: Wednesday, Aug. 29th 08:00 – 18:00

Thursday, Aug. 30th 09:00 – 17:00

Friday, Aug. 31st 09:00– 17:00


71

his majesty king abdullah ii ibn al-hussein · president of the european association of nuclear...

Documents